This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (38) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Blanco, F J Articles by Pascual, E Search for Related Content PubMed PubMed Citation Articles by Blanco, F J Articles by Pascual, E Pubmed/NCBI databases Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Survival analysis of 306 European Spanish patients with systemic lupus erythematosus

J J Gómez-Reino

J de la Mata

Hospital 12 de Octubre, Madrid

A Corrales

V Rodríguez-Valverde

Hospital Marqués de Valdecilla, Santander

J C Rosas

Hospital General de Alicante

A Gómez de la Camara

Hospital 12 de Octubre, Madrid

E Pascual

Hospital General de Alicante

Objective: To describe survival of lupus in South European Spanish patients.

Patients and Methods: Observational study of all SLE Spanish patients seen at three University Hospitals between 1975 and 1993. The charts of all patients were retrospectively reviewed. Sixtyfour clinic and laboratory variables were extracted from charts. Univariate analysis, multivariate Cox proportional hazard regression analysis, actuarial life tables and multiple logistic regression analysis were used to calculate survival probability and identify variables associated with survival.

Results: Three hundred and six (275 female and 31 male) patients were identified. Their mean age at diagnosis was 31.9 years (range 4 to 85). The mean duration of followup was 79 (1—126) months. Thirty-one patients died. The most common cause of death was infection (29%). Five, 10 and 15 years' survival rate was 90%–0.0158, 85%–0.0262 and 80%–0.0413, respectively. Log-rank analysis showed that male sex, proteinuria and nephropathy at diagnosis were associated with poor survival. By univariate and multivariate analysis male gender, nephropathy and CNS involvement were associated with worse survival.

Conclusion: In SLE patients from Spain, rate of survival is similar to other Caucasian patients, and better than other ethnic groups of Spanish ancestry. Other factors rather than genetic factors could explain our findings.

Key Words: Systemic lupus erythematosus • Survival in lupus • Predictors of mortality • Causes of death • Caucasian southeuropean lupus

Lupus, Vol. 7, No. 3, 159-163 (1998)
DOI: 10.1191/096120398678919930


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L-J. Lu, D. Wallace, M. Ishimori, R. Scofield, and M. Weisman Review: Male systemic lupus erythematosus: a review of sex disparities in this disease Lupus, February 1, 2010; 19(2): 119 - 129. [Abstract] [PDF]

				C. Cardoso, F. Signorelli, J. Papi, and G. Salles Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study Lupus, November 1, 2008; 17(11): 1042 - 1048. [Abstract] [PDF]

				M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system Ann Rheum Dis, April 1, 2007; 66(4): 470 - 475. [Abstract] [Full Text] [PDF]

				A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco Mycophenolate mofetil and systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 44 - 54. [Abstract] [PDF]

				X Bosch, A Guilabert, L Pallares, R Cervera, M Ramos-Casals, A Bove, M Ingelmo, and J Font Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients Lupus, September 1, 2006; 15(9): 584 - 589. [Abstract] [PDF]

				R. Bessant, A. Hingorani, L. Patel, A. MacGregor, D. A. Isenberg, and A. Rahman Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus Rheumatology, July 1, 2004; 43(7): 924 - 929. [Abstract] [Full Text] [PDF]

				P Lopez, L Mozo, C Gutierrez, and A Suarez Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features Lupus, November 1, 2003; 12(11): 860 - 865. [Abstract] [PDF]

				S Bujan, J Ordi-Ros, J Paredes, M Mauri, L Matas, J Cortes, and M Vilardell Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients Ann Rheum Dis, September 1, 2003; 62(9): 859 - 865. [Abstract] [Full Text] [PDF]

				K Manger, B Manger, R Repp, M Geisselbrecht, A Geiger, A Pfahlberg, T Harrer, and J R Kalden Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus Ann Rheum Dis, December 1, 2002; 61(12): 1065 - 1070. [Abstract] [Full Text] [PDF]

				D D Gladman, F Hussain, D Iban, and M B Urowitz The nature and outcome of infection in systemic lupus erythematosus Lupus, April 1, 2002; 11(4): 234 - 239. [Abstract] [PDF]

				M Helbert, S Bodger, J Cavenagh, D D'Cruz, J M Thomas, and P MacCallum Optimising testing for phospholipid antibodies J. Clin. Pathol., September 1, 2001; 54(9): 693 - 698. [Abstract] [Full Text] [PDF]

				M. B. Urowitz and D. D. Gladman How to improve morbidity and mortality in systemic lupus erythematosus Rheumatology, March 1, 2000; 39(3): 238 - 244. [Full Text] [PDF]

				S J Pu, S F Luo, Y J J Wu, H S Cheng, and H H Ho The clinical features and prognosis of lupus with disease onset at age 65 and older Lupus, February 1, 2000; 9(2): 96 - 100. [Abstract] [PDF]